EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 8.3

Change

+0.15 (+1.84)%

Market Cap

N/A

Volume

0.54M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.42 (+0.26%)

USD 74.37B
HLN Haleon plc

+0.02 (+0.21%)

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.24B
RDY Dr. Reddy’s Laboratories Ltd..

+0.18 (+1.16%)

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

+0.02 (+0.17%)

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.06 (+0.77%)

USD 3.59B
BHC Bausch Health Companies Inc

+0.05 (+0.67%)

USD 2.75B
CPHI China Pharma Holdings Inc

+0.01 (+5.00%)

USD 3.69M
YCBD cbdMD Inc

+0.01 (+2.28%)

USD 1.96M

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 21.86 % 0.00 %

N/A

USD 0.05B
XB4A:XETRA Xtrackers ATX UCITS ETF 1.. 21.57 % 0.00 %

N/A

USD 0.05B
EXXX:XETRA iShares ATX UCITS ETF (DE.. 21.24 % 0.00 %

N/A

USD 0.09B
EBNK:CA Evolve European Banks Enh.. 5.18 % 0.00 %

+0.04 (+0.36%)

CAD 5.35M
IS3H:XETRA iShares MSCI EMU Mid Cap .. 1.93 % 0.00 %

N/A

USD 0.13B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.93 % 0.00 %

N/A

USD 0.14B
FTEU:LSE First Trust Eurozone Alph.. 1.35 % 0.00 %

+0.20 (+0.36%)

USD 0.06B
FEUZ:LSE First Trust Eurozone Alph.. 1.34 % 0.00 %

+5.75 (+0.36%)

USD 0.06B
FEUD:LSE First Trust Eurozone Alph.. 1.34 % 0.00 %

+9.00 (+0.36%)

USD 0.01B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+1.60 (+0.36%)

N/A
FTGE:XETRA First Trust Eurozone Alph.. 1.18 % 0.00 %

N/A

USD 0.08B
EUMD:LSE iShares MSCI Europe Mid C.. 1.16 % 0.00 %

+0.03 (+0.36%)

USD 0.27B
FEUZ First Trust Eurozone Alph.. 0.00 % 0.80 %

+0.11 (+0.36%)

USD 0.06B
PRFZ Invesco FTSE RAFI US 1500.. 0.00 % 0.39 %

+0.34 (+0.36%)

USD 2.74B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 245.83% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 245.83% 100% F 100% F
Trailing 12 Months  
Capital Gain 244.40% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 244.40% 100% F 99% N/A
Trailing 5 Years  
Capital Gain -84.69% 21% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.69% 21% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -21.69% 7% C- 2% F
Dividend Return -21.69% 7% C- 2% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 94.37% 20% F 9% A-
Risk Adjusted Return -22.98% 20% F 10% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector